Trial NCT04871542

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

This study examines how certain risk factors (such as age, gender, other medical conditions,
and the type of immunotherapy used to treat the cancer) affect whether a patient with a
malignant solid tumor will develop mild or serious side effects from the immunotherapy
medications. Immunotherapy is the type of treatment that helps the body's immune system fight
cancer. In the future, this information may help doctors make better decisions about cancer
treatments.

Intervention

Biospecimen Collection, Questionnaire Administration

Condition

Malignant Solid Neoplasm

Investigators

Krishna S Gunturu, Debra M. Prow

See list of participating sites